Agios cuts 100-plus R&D roles as FDA decision slips

By Rebecca Stone

Agios Pharmaceuticals will eliminate 100-plus research and development (R&D) positions, cutting more than 35% of its R&D staff, and expects about $11 million in restructuring charges this year.

Agios made the announcement Thursday as the Food and Drug Administration (FDA) delayed a decision on mitapivat for sickle cell disease from the previously expected Nov. 1 to Feb. 1, 2027. The company expects savings from the workforce reduction to emerge in 2027. It now projects a profit, excluding irregular or non-recurring costs, in 2028.

Agios employed 539 full-time workers across the organization as of December 2025. The Thursday release did not state the exact number of research positions remaining, so the reported percentage, rather than a final laboratory headcount, defines the scale of the reduction.

How is Agios reallocating R&D capital?

On Thursday’s earnings call, CEO Brian Goff said Agios had “right sized” its operating model to align with its next phase of growth. He said the strategy would “maximize the mitapivat franchise,” the company’s oral pyruvate kinase activator.

The plan combines workforce reduction with a focus on two mid- to late-stage rare hematology candidates and a stronger commercial emphasis. Analysts viewed those changes favorably. In a Friday note, Leerink Partners said the R&D headcount cut reflects sharper capital allocation toward commercialization and focused late-stage development, consistent with Agios’s increasing commercial emphasis.

Agios also remains open to unlocking value from non-core assets. These include AG-181, an investigational PAH stabilizer in early-stage development for phenylketonuria, a rare inherited metabolic disorder. The company has announced no transaction, partner or timetable, leaving the near-term budget effect unspecified.

How large is the approved product base?

Mitapivat, an oral pyruvate kinase activator, has approval in pyruvate kinase deficiency under the name Pyrukynd and in thalassemia under the name Aqvesme. Together, the products generated $55.4 million in global net revenue in the third quarter.

Agios reported 24% growth from the preceding quarter and revenue above the $51.9 million analyst consensus. This is a measured result, whereas the restructuring charge, 2027 savings and 2028 profitability estimate are company projections. The contrast sets a clear budget test: Agios must convert its approved products into lower operating costs without weakening the two priority hematology programs.

Why did the FDA extend the review?

Agios had expected an FDA decision by Nov. 1. The agency requested more information about a potential safety protocol. Regulators assessed whether mitapivat needed a Risk Evaluation and Mitigation Strategy (REMS), a formal program for evaluating and reducing drug-safety risks. In an Oct. 30 release, Agios said the FDA considered its response a major amendment to the drug application.

Both Pyrukynd and Aqvesme carry liver safety warnings. Only Aqvesme has a formal REMS, based on several liver adverse events during thalassemia clinical testing. Agios reported no similar hepatocellular injury cases in sickle cell disease so far.

Agios did not provide patient numbers, event rates or follow-up duration, so the absence of reported cases cannot establish absence of risk. The company materials also supplied no new efficacy dataset; the FDA request concerned safety protocol and labeling.

Agios has maintained that it remains launch-ready and will continue labeling discussions with the FDA during the ongoing review. That readiness statement reflects the company’s preparation, not an FDA conclusion on the delayed indication.

What has the restructuring changed for investors?

The stock fell more than 15% to $29.95 per share after the FDA delay. It continued downward in Friday premarket trading to $28.27. Truist Securities wrote in a Thursday morning investor note: “Cost discipline provides another lever toward profitability.”

Agios reported $907 million in cash and marketable securities as of Sept. 30. That balance sits against launch spending and the selected late-stage programs, but the company disclosed no program-level budget or forecast for deploying it.

What has to happen next?

The next hard checkpoint is the FDA’s scheduled Feb. 1, 2027 decision. Agios also must show whether the projected $11 million charge produces savings in 2027 and whether its two priority hematology programs can support the 2028 profitability estimate while management considers options for AG-181 and other non-core assets.